Pricing Log in Create free account
Saturday 17 October 2026 Export NIKI’s income statement to Excel — free account

Niki BioSolutions, Inc.

NIKI Healthcare Biotechnology

Niki BioSolutions, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $431,400.00, down 66.7% from fiscal 2022.

2.03 0.19 −8.56%
Market cap
$6.9M
P/E
0.0×
Fwd P/E
31.9×
Dividend yield
—
F-score
2/9
Altman Z
−5.03
Beneish M
−1.39
Dividend safety
n/a
Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 86.75%

Capital & Financial Ratios $m

Market Cap 6.92
Revenue 2.63
Net Income (5.53)
Free Cash Flow (2.90)
Net Debt (0.03)
Current Ratio 0.78 (below 1: weak)
Debt/Equity 0.25 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E 31.90
P/S ratio 0.00
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth —
Next Y EPS Growth —
Next Y revenue growth 515,199.03% (at or above 10%: strong)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.3×, against a ten-year median of 0.5×; over the ten years it ranged from −20.3× in 2020 to 2.1× in 2024.
EV/Sales against its own 10 years 73.71%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2026 Powerpack
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2022 2023 2024 2025
Cash 5 2 1 3
Receivables 2 0 0 0
Inventory 0 — — —
Other 0 — — —
7 2 1 4
2022 2023 2024 2025
Payables 6 2 1 1
ST’ Debt 6 — 3 3
Other — — — —
13 2 4 5

Compound Annual Growth %

10y 5y 3y
Sales — 2.38% (22.07%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (18.47%) 20.61%

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’23 — — — — 0
’22 — — — — 1
’21 — — — — 2
’20 — — — — 1
’19 — — — — 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — (1) 0 (1) (2)
’24 — (1) — (1) (1)
’23 — (6) — (8) (8)
’22 — (7) — (12) (12)
’21 — (7) — (15) (15)
’20 — (7) — (16) (16)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — (1) 0 (1) (2)
’24 — (1) — (1) (1)
’23 — (6) — (8) (8)
’22 — (7) — (12) (13)
’21 — (7) — (15) (15)
’20 — (7) — (16) (15)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — (1.90)
’24 — — — — (7.80)
’23 — — — — (6.20)
’22 — — — — (27.50)
’21 — — — — (71.00)
’20 — — — — 20.00
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — 1,325.00 1,180.00 116.00 147.00 40.00 13.60 4.60 6.90

Analyst estimates 2026–2028

Powerpack
High — — 1,585.00 3,328.00 1,825.00 494.00 235.00 90.00 174.90 48.00
People
People Employees — 46 41 37 26 26 19 3 1 2
Revenue/emp, $m — 0.00 0.01 0.01 0.04 0.06 0.07 0.14 0.00 0.00
Income, $m
Income, $m Revenue — — 0 1 1 2 1 0 — —
Gross margin, % — 0.00 17.05 (48.47) (11.35) 5.31 6.18 2.46 — —
EBT — 0 (15) (20) 5 (27) (12) (4) (4) (1)
EBT margin, % — 0.00 (3,946.41) (3,758.76) 539.79 (1,758.61) (889.35) (1,006.26) 0.00 0.00
Net income — 0 (15) (20) 5 (27) (12) (4) (4) (1)
Depreciation — 0 1 1 1 1 1 1 0 —
Per share, $
Per share, $ Revenue — 0.00 1.37 1.84 2.93 4.40 3.63 0.95 0.00 0.00
Earnings — (0.85) (53.00) (64.00) 20.00 (71.00) (27.50) (6.20) (7.80) (1.90)
Cash flow — 0.00 (35.96) (46.13) (51.16) (41.83) (34.52) (17.09) (2.18) (2.50)
Capex — 0.00 (21.73) (3.13) 2.86 (0.41) (0.52) 0.03 0.11 0.00
Free cash flow — 0.00 (57.68) (49.26) (48.30) (42.24) (35.04) (17.06) (2.07) (2.50)
Book value — 10.04 117.33 51.20 122.52 49.97 21.95 34.03 21.60 18.70
Shares, m — 3 0 0 0 0 0 0 1 1
Valuation, ×
Valuation, × P/E — — 0.00 0.00 254.64 0.00 0.00 0.00 — —
P/S — — 0.00 0.00 0.00 0.00 0.00 0.00 — —
P/B — — 0.00 0.00 0.00 0.00 0.00 0.00 — —
EV/Sales — — 0.00 0.00 (20.27) (3.37) 0.49 0.55 — —
EV/FCF — — 0.00 0.00 0.56 0.19 (0.03) (0.04) — —
Cash, $m
Cash, $m Operating cash flow — 0 (10) (13) (16) (15) (12) (8) (1) (2)
Capex — 0 (6) (1) 1 0 0 0 0 —
Free cash flow — 0 (16) (14) (15) (15) (13) (8) (1) (2)
Balance, $m
Balance, $m Working capital — 19 17 5 30 8 (5) 0 (3) (1)
Total debt — 0 10 7 3 0 7 3 3 3
Net debt — (19) (17) 0 (29) (8) 1 1 2 0
Shareholders’ equity — 30 33 15 38 18 8 15 12 14
Returns, %
Returns, % ROA — (6.65) (38.71) (54.14) 18.51 (75.75) (45.82) (13.61) (23.21) (7.83)
ROIC — 0.00 (40.96) (76.81) (143.66) (129.97) (118.55) (40.78) (17.42) (8.29)
ROE — (8.04) (47.10) (78.52) 23.81 (90.01) (77.35) (24.33) (31.43) (10.68)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2023 · latest quarter Jan 0001 · fundamentals updated 5 Oct 2026

Charts ten years each

Niki BioSolutions, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
XCUR Exicure, Inc. $7.3M — (loss-making) — (loss-making) −80.51% (below 0%: shrinking) n/m +65.38% (above 0%: growing) 100.00% 0.00% Compare
SKYE Skye Bioscience, Inc. $7.0M — (loss-making) — −34.71% (below 0%: shrinking) n/m +34.84% (above 0%: growing) 72.71% 0.00% Compare
BCLI Brainstorm Cell Therapeutics Inc. $7.0M — (loss-making) — — n/m +74.44% (above 0%: growing) 0.00% 0.00% Compare
CLGN CollPlant Biotechnologies Ltd. Sponsored ADR $7.0M — (loss-making) — (loss-making) −39.66% (below 0%: shrinking) n/m +5.08% (above 0%: growing) (422.22%) (2,437.96%) Compare
NIKI Niki BioSolutions, Inc. $6.9M — (loss-making) 31.9× −32.36% (below 0%: shrinking) +69.51% (above 0%: growing) +58.14% (above 0%: growing) (154.22%) 0.00%
AIM AIM ImmunoTech Inc. $6.8M — (loss-making) — (loss-making) +4.00% (above 0%: growing) n/m −167.46% (below 0%: shrinking) 80.77% (13,511.54%) Compare
SYBX Synlogic, Inc. $6.7M — (loss-making) — (loss-making) −95.40% (below 0%: shrinking) n/m −277.87% (below 0%: shrinking) 100.00% 0.00% Compare
FBLG FibroBiologics Inc. $6.7M — (loss-making) — — n/m +21.59% (above 0%: growing) — 0.00% Compare
ACXP Acurx Pharmaceuticals, Inc. $6.5M — (loss-making) — — n/m −2.36% (below 0%: shrinking) — 0.00% Compare
Median of peers $6.9M — — −39.66% — +13.34% 76.74% 0.00%

All 614 Biotechnology stocks →

Niki BioSolutions, Inc. (NIKI) key facts

  • Concern: Niki BioSolutions, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $431,400.00, down 66.7% from fiscal 2022.
  • Niki BioSolutions, Inc. (NIKI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, NIKI traded at $2.03, a market capitalization of $6.9 million.
  • Return on equity was −10.7% and debt-to-equity 0.25.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −5.03 (distress zone) for fiscal 2023.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 5, 2026.

Niki BioSolutions, Inc. (NIKI) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/NIKI · Data as of Oct 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com